Potential conflict of interest: JDO is a consultant to TEVA Pharmaceuticals; he received no financial support for this manuscript.
Pathophysiology of and potential new therapies for allergic rhinitis
Article first published online: 28 NOV 2012
© 2013 ARS-AAOA, LLC
International Forum of Allergy & Rhinology
Volume 3, Issue 5, pages 384–392, May 2013
How to Cite
How to Cite this Article: Pathophysiology of and potential new therapies for allergic rhinitis. Int Forum Allergy Rhinol, 2013; 3:384–392.
- Issue published online: 17 MAY 2013
- Article first published online: 28 NOV 2012
- Manuscript Accepted: 10 OCT 2012
- Manuscript Received: 29 AUG 2012
- T-helper lymphocyte;
- mast cell;
- humanized monoclonal antibody;
Advancement in laboratory techniques in the past decade, coupled with clinical studies, has afforded a better understanding of the genetic and molecular mechanisms underlying allergy.
The literature on the pathophysiology of allergic rhinitis, systemic and local, was reviewed, with emphasis on the last 3 years.
The basis in allergic rhinitis for the T-lymphocyte helper 2 cell and associated cytokine bias, and the ameliorating effects of T-regulatory lymphocytes and their cytokines, is summarized. New or currently under development pharmacotherapeutic agents are briefly presented.
Much of the molecular basis for the manifestations of allergy can now be explained, and may afford strategies to interrupt the development of disease or ameliorate such already present.